Publications

Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study

Publié en January 2019 JOURNAL OF INVESTIGATIVE DERMATOLOGY
January 2019

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Previous publication
January 2019

Role of quantitative computed tomography in patients with severe precapillary pulmonary hypertension

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Next publication

Authors